These findings have led to discussions of strategies toreverse the effects of mutations, especially mutations that result in silencingof the expression of one or more subunits, as a novel epigenetics-based approachto cancer therapy [48–50].In addition, considerable attention has been given to the idea of inducingsynthetic lethality; targeting the BRM ATPase in cancers already containingnonfunctional BRG1 may be an effective strategy to treat such tumors [51–53]. Here, SMARCA4 is linked to cancer.